AS ANTIBIOTIC RESISTANCE GROWS, STUDY SHOWING HOW SUPERBUGS KILL OTHERS OFFERS HOPE
Bacteria resistant to antibiotics are linked to millions of deaths per year, but researchers may have found a way to defeat them
Daria Van Tyne did not expect to see changes in a population of bacteria taken from her hospital in Pennsylvania, in the United States.
Her hunch was wrong, but the results of her recent study point to a potential solution for antibiotic resistance.
Bacteria are ancient organisms that have learned advanced evolutionary behaviours over billions of years.
Do you have questions about the biggest topics and trends from around the world? Get the answers with SCMP Knowledge, our new platform of curated content with explainers, FAQs, analyses and infographics brought to you by our award-winning team.
The particular strain Van Tyne was studying, Enterococcus faecium, exists in the guts of humans and many animals and is hard to kill.
"As a researcher, I'm very interested in how the bacteria that make people sick in the hospital are evolving and changing over time," says Van Tyne, an associate professor of medicine at the University of Pittsburgh School of Medicine's Division of Infectious Diseases.
She is the senior author of a recent paper, published in the medical journal Nature Microbiology, which found three new strains of drug-resistant Enterococcus faecium, some with the capacity to completely wipe out their neighbours.
The researchers hope their findings can be used to develop a potent medicine to treat bacterial resistance, a growing problem in a world teeming with antibiotic prescription and unbalanced gut microbiomes.
The World Health Organization has deemed antibiotic resistance a key global threat to public health, directly responsible for 1.27 million deaths in 2019 and associated with 4 million others.
More than 39 million people will die from antibiotic resistance by 2050, one analysis published in Nature suggests, if innovative measures are not taken.
Because of their ubiquity, Enterococci frequently infect patients in hospitals, leading to bloodstream and urinary infections.
These are typically treated with the antibiotic vancomycin, but strains that are resistant to it - called vancomycin-resistant Enterococcus faecium, or VRE - have emerged.
"I call them the cockroaches of the human microbiome," Van Tyne jokes.
The US Centres for Disease Control and Prevention says VRE caused an estimated 54,000 infections in patients in hospitals throughout the US in 2017, and 10 per cent of those infected patients died.
Van Tyne and her laboratory were able to access the genomes of 710 samples collected between 2017 abd 2022 at a nearby University of Pittsburgh Medical Centre (UPMC) hospital through a large database, called the Enhanced Detection System for Hospital-Associated Transmission (EDS-HAT) whole-genome sequencing surveillance programme.
It helps hospitals track how bacterial infections spread among patients.
"We simply wanted to know, are there any detectable changes in the bacterial population over this six-year time frame?" she says.
"We were pleasantly surprised when we did see this very dramatic change in the population of bacteria causing infections in people in the hospital. That first observation kicked it all off."
Similar to how coronavirus variants evolve and eclipse each other over time, bacterial strains are constantly at war, competing to outlive one another.
Over the six-year period, the diversity of the VRE strains bottlenecked from eight to two dominant strains, which showed up in 80 per cent of samples from 2022.
After peering into the genetic codes of those 710 samples, researchers discerned how those two strains gained prominence over the others.
They found genes associated with increased ability to replicate and better kill other bacterial cells.
They also discovered all the dominant strains developed a collection of proteins, called a bacteriocin - an antibiotic bacteria made to kill others.
This bacteriocin allowed these strains to have a competitive advantage over the others, catapulting them into dominance.
"The bacteriocin is just like a pin," Van Tyne says. If other cells are the balloons it easily pops them, exploding their contents and killing them.
"The new strain with this bacteriocin completely wiped out the old strain in every mouse that we looked at, which was really reflective of what we saw in the hospital," says Emma Mills, first author on the paper and a PhD candidate in Pittsburgh Medicine's microbiology and immunology department. "It was very drastic.
"The idea is that if these specific VRE in patients' gastrointestinal tract produce this bacteriocin, they're able to kill their neighbour, eat their food and snatch it up, which makes a really great competitive advantage in the GI tract."
It is thought that nearly every bacterial species has the capacity to produce a bacteriocin, but researchers are still working to identify them all.
Some bacteriocins occur naturally in dairy and fish products, and ward off worse food-borne pathogens.
These natural antibiotics have been studied across the globe for decades for their potential to target antibiotic resistance. One 2015 study found that a bacteriocin inhibited the growth of listeria, a rare but deadly food-borne pathogen.
Bacteriocins have also been shown throughout scientific literature to be non-toxic, in contrast to pharmaceutical antibiotics with longer lasting side-effects.
In their study, Van Tyne and Mills wanted to explore whether these hardy bacteriocin-producing bacteria were unique to UPMC and the 710 sample pool.
Using a global genetic sequencing database of 15,000 VRE samples taken from 2002 to 2022, they found that the dominant strains they identified were persistent in the hospitals of other countries, including Australia and Denmark.
"Surprisingly, this local phenomenon was actually playing out on a global scale," Van Tyne says.
"We do see such a strong and powerful signal that bacteriocins can truly shape populations of microbes within healthcare systems," Mills says. "So we could definitely leverage that as a weapon."
With modern gene sequencing, discovering potential treatments like bacteriocins is easier than ever. Van Tyne and Mills are continuing their research in this area to see how VRE strains are changing over time.
"The silver lining here is that there are many fewer strains of VRE we now worry about treating," Van Tyne says.
"We can focus our efforts on developing new therapeutic approaches for VRE infections with the small number of strains that are currently circulating."
Like what you read? Follow SCMP Lifestyle on Facebook, X and Instagram. You can also sign up for our eNewsletter here.
More Articles from SCMP
Presence of Indonesian students in Israel stirs debate over Jakarta’s Palestine stance
China invites European countries to form united front against Trump tariffs
3 arrested in Hong Kong over 2,000 fake HK$500 million ‘bonds’
UN experts to assess Hong Kong’s rescue team for accreditation next year
This article originally appeared on the South China Morning Post (www.scmp.com), the leading news media reporting on China and Asia.
Copyright (c) 2025. South China Morning Post Publishers Ltd. All rights reserved.
2025-04-23T09:54:52Z
